Hi, welcome to Spherix!
We are a hyper-focused market intelligence firm that leverages our own independent data & expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence.We specialize in select dermatology, gastroenterology, nephrology, neurology, ophthalmology, and rheumatology markets.
Spherix’s coverage of the neovascular age-related macular degeneration (nAMD) market focuses on the current VEGF treatment landscape and the upcoming shift in the treatment paradigm, particularly the expansion of intravitreal biologic options, new MOAs, and introduction of biosimilars.
Our coverage of diabetic eye disease focuses on diabetic macular edema and diabetic retinopathy – providing the big-picture analysis of the current market landscape, including ophthalmologists’ understanding, diagnosis, and treatment of the disease while monitoring perceptions and uptake of new entrants.
At Spherix, the report is only part of the deliverable. Our insights are customized to your business needs and we thrive on delivering not just data, but context. Our experts provide input and interpretation of the findings to finely tune the final reports.
Brands: Market Dynamix (pipeline evaluation); RealTime Dynamix (ongoing monitoring of established markets); Launch Dynamix (launch tracking); RealWorld Dynamix (patient level data)